Express Mail No. EV51986700311S

## INFORMATION DISCLOSURE **STATEMENT UNDER 37 CFR § 1.97(D)**

Commissioner for Patents

Wali No. E v 31700700		
Attorney Docket	BEAR-006CIP	/ (
First Named Inventor	KUMAGAI, YOSHINARI	
Application Number	09/812,485	
Filing Date	March 19, 2001	
Group Art Unit	1653	
Examiner Name	KAM, CHIH MIN	

Title: "INTEGRIN BINDING MOTIF CONTAINING PEPTIDES AND METHODS OF TREATING

SKELETAL DISEASES"

Sir:

Address to:

Mail Stop AF

P.O. Box 1450

This is an Information Disclosure Statement submitted for the Examiner's consideration. This is being filed after a Final Action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311, whichever occurs first, but before, or simultaneously with, the payment of the issue fee.

A Form SB08 (substitute for form 1449) listing the references accompanies this paper. Applicants would appreciate the Examiner initialing and returning the form to indicate that the references have been reviewed and made of record.

## Statement(s) under 37 CFR § 1.97(e):

- $\boxtimes$ (1) That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or
- (2) That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

This Information Disclosure Statement is not intended as a representation that a search has been made. that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

12/06/2004 LWONDIH1 00000004 500815 09812485 180.00 DA 01 FC:1806

Atty Dkt. No.: BEAR-006CIP

USSN: 09/812,485

specified in 37 C.F.R. §1.97(e). Applicant(s) hereby petition for the consideration of this Information Disclosure Statement.

The \$180.00 fee set forth in 37 C.F.R. §1.17(p) to cover the petition accompanies this disclosure statement. The Office is hereby authorized to charge any additional fees which may be required by this paper or any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21, or to credit any overpayment, to our Deposit Account No. 50-0815, Order No. BEAR-006CIP may be charged thereon.

Respectfully submitted, BOZICEVIC, FIELD & FRANCIS LLP

Date:

By:

arl Bozicevic (Reg. No. 28,80°

BOZICEVIC, FIELD & FRANCIS LLP 1900 University Avenue, Suite 200

East Palo Alto, California 94303 Telephone: (650) 327-3400 Facsimile: (650)327-3231

PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO				Complete if Known		
		Application Number	09/812,485			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			URE	Filing Date	March 19, 2001	
			ANT	First Named Inventor	Kumagai	
				Group Art Unit	1653	
(use as many sheets as necessary)				Examiner Name	C. Kam	
Sheet	1	of	1	Attorney Docket Number	BEAR-006CIP	

OTHER ART—NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the artition item (book, magazine, journal, serial, symposium, catalog, etc.), date	e, page(s), volum	priate), title of the ne-issue number(s),	T²		
		Lopez-Moratalla et al., "A common structural motif in immuno present in human autoantigens. Elicitation of a response me Biochimica et Biophysica Acta, Vol. 1317, No. 3, 1996, pgs. 183-19	ediated by m	peptides with sequences onocytes and Th1 cells"			
Examiner	T		Date				
Signature			Considered				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.